TY - JOUR
T1 - Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
AU - The Cancer Genome Atlas Research Network
AU - Campbell, Joshua D.
AU - Yau, Christina
AU - Bowlby, Reanne
AU - Liu, Yuexin
AU - Brennan, Kevin
AU - Fan, Huihui
AU - Taylor, Alison M.
AU - Wang, Chen
AU - Walter, Vonn
AU - Akbani, Rehan
AU - Byers, Lauren Averett
AU - Creighton, Chad J.
AU - Coarfa, Cristian
AU - Shih, Juliann
AU - Cherniack, Andrew D.
AU - Gevaert, Olivier
AU - Prunello, Marcos
AU - Shen, Hui
AU - Anur, Pavana
AU - Chen, Jianhong
AU - Cheng, Hui
AU - Hayes, D. Neil
AU - Bullman, Susan
AU - Pedamallu, Chandra Sekhar
AU - Ojesina, Akinyemi I.
AU - Sadeghi, Sara
AU - Mungall, Karen L.
AU - Robertson, A. Gordon
AU - Benz, Christopher
AU - Schultz, Andre
AU - Kanchi, Rupa S.
AU - Gay, Carl M.
AU - Hegde, Apurva
AU - Diao, Lixia
AU - Wang, Jing
AU - Ma, Wencai
AU - Sumazin, Pavel
AU - Chiu, Hua Sheng
AU - Chen, Ting Wen
AU - Gunaratne, Preethi
AU - Ding, Li
AU - Fulton, Lucinda A.
AU - Fulton, Robert S.
AU - DiPersio, John
AU - Drake, Bettina
AU - Govindan, Ramaswamy
AU - Ley, Timothy
AU - Van Tine, Brian
AU - Westervelt, Peter
N1 - Funding Information:
We are grateful to the patients who contributed to this study, and the support of the TCGA Steering Committee and Project Team, especially Samantha Caesar-Johnson and Ina Felau. This work was supported by the following grants from the NIH : U54 HG003273 , U54 HG003067 , U54 HG003079 , U24 CA143799 , U24 CA143835 , U24 CA143840 , U24 CA143843 , U24 CA143845 , U24 CA143848 , U24 CA143858 , U24 CA143866 , U24 CA143867 , U24 CA143882 , U24 CA143883 , U24 CA144025 , and P30 CA016672 , and NIDCD intramural project ZIA-DC-000074 .
Funding Information:
Michael Seiler, Peter G. Smith, Ping Zhu, Silvia Buonamici, and Lihua Yu are employees of H3 Biomedicine, Inc. Parts of this work are the subject of a patent application, WO2017040526 titled “Splice variants associated with neomorphic sf3b1 mutants.” Shouyoung Peng, Anant A. Agrawal, James Palacino, and Teng are employees of H3 Biomedicine, Inc. Andrew D. Cherniack, Ashton C. Berger, and Galen F. Gao receive research support from Bayer Pharmaceuticals. Gordon B. Mills serves on the External Scientific Review Board of Astrazeneca. Anil Sood is on the Scientific Advisory Board for Kiyatec and is a shareholder in BioPath. Jonathan S. Serody receives funding from Merck, Inc. Kyle R. Covington is an employee of Castle Biosciences, Inc. Preethi H. Gunaratne is founder, CSO, and shareholder of NextmiRNA Therapeutics. Christina Yau is a part-time employee/consultant at NantOmics. Franz X. Schaub is an employee and shareholder of SEngine Precision Medicine, Inc. Carla Grandori is an employee, founder, and shareholder of SEngine Precision Medicine, Inc. Robert N. Eisenman is a member of the Scientific Advisory Boards and shareholder of Shenogen Pharma and Kronos Bio. Daniel J. Weisenberger is a consultant for Zymo Research Corporation. Joshua M. Stuart is the founder of Five3 Genomics and shareholder of NantOmics. Marc T. Goodman receives research support from Merck, Inc. Andrew J. Gentles is a consultant for Cibermed. Charles M. Perou is an equity stock holder, consultant, and Board of Directors member of BioClassifier and GeneCentric Diagnostics and is also listed as an inventor on patent applications on the Breast PAM50 and Lung Cancer Subtyping assays. Matthew Meyerson receives research support from Bayer Pharmaceuticals; is an equity holder in, consultant for, and Scientific Advisory Board chair for OrigiMed; and is an inventor of a patent for EGFR mutation diagnosis in lung cancer, licensed to LabCorp. Eduard Porta-Pardo is an inventor of a patent for domainXplorer. Han Liang is a shareholder and scientific advisor of Precision Scientific and Eagle Nebula. Da Yang is an inventor on a pending patent application describing the use of antisense oligonucleotides against specific lncRNA sequence as diagnostic and therapeutic tools. Yonghong Xiao was an employee and shareholder of TESARO, Inc. Bin Feng is an employee and shareholder of TESARO, Inc. Carter Van Waes received research funding for the study of IAP inhibitor ASTX660 through a Cooperative Agreement among NIDCD, NIH, and Astex Pharmaceuticals. Raunaq Malhotra is an employee and shareholder of Seven Bridges, Inc. Peter W. Laird serves on the Scientific Advisory Board for AnchorDx. Joel Tepper is a consultant at EMD Serono. Kenneth Wang serves on the Advisory Board for Boston Scientific, Microtech, and Olympus. Andrea Califano is a founder, shareholder, and advisory board member of DarwinHealth, Inc. and a shareholder and advisory board member of Tempus, Inc. Toni K. Choueiri serves as needed on advisory boards for Bristol-Myers Squibb, Merck, and Roche. Lawrence Kwong receives research support from Array BioPharma. Sharon E. Plon is a member of the Scientific Advisory Board for Baylor Genetics Laboratory. Beth Y. Karlan serves on the Advisory Board of Invitae.
Publisher Copyright:
© 2018
PY - 2018/4/3
Y1 - 2018/4/3
N2 - This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the ΔNp63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy. These findings support possibilities for molecular classification and therapeutic approaches. Campbell et al. reveal that squamous cell cancers from different tissue sites may be distinguished from other cancers and subclassified molecularly by recurrent alterations in chromosomes, DNA methylation, messenger and microRNA expression, or by mutations. These affect squamous cell pathways and programs that provide candidates for therapy.
AB - This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the ΔNp63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy. These findings support possibilities for molecular classification and therapeutic approaches. Campbell et al. reveal that squamous cell cancers from different tissue sites may be distinguished from other cancers and subclassified molecularly by recurrent alterations in chromosomes, DNA methylation, messenger and microRNA expression, or by mutations. These affect squamous cell pathways and programs that provide candidates for therapy.
KW - bladder carcinoma with squamous differentiation
KW - cervical squamous cell carcinoma
KW - esophageal squamous cell carcinoma
KW - genomics
KW - head and neck squamous cell carcinoma
KW - human papillomavirus
KW - lung squamous cell carcinoma
KW - proteomics
KW - transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85044610513&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2018.03.063
DO - 10.1016/j.celrep.2018.03.063
M3 - Article
C2 - 29617660
AN - SCOPUS:85044610513
SN - 2639-1856
VL - 23
SP - 194-212.e6
JO - Cell Reports
JF - Cell Reports
IS - 1
ER -